SpyGlass Pharma Stock Price, News & Analysis
Company Description
SpyGlass Pharma (NASDAQ: SGP) is a publicly traded company in the Surgical & Medical Instruments & Apparatus sector. The company has a market capitalization of $839.6M, ranking #2,973 among all listed U.S. companies by market cap.
SGP stock has declined 14.4% over the past year. Shares last traded at $22.61.
On a trailing twelve-month basis, SpyGlass Pharma reported net income of -$39.9M and diluted earnings per share of $-17.98.
This page provides a comprehensive overview of SGP stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
SpyGlass Pharma (SGP) stock last traded at $22.61, down 10.63% from the previous close. Over the past 12 months, the stock has lost 14.4%. At a market capitalization of $839.6M, SGP is classified as a small-cap stock with approximately 33.4M shares outstanding.
Latest News
SpyGlass Pharma has 5 recent news articles, with the latest published 2 days ago. Of the recent coverage, 2 articles coincided with positive price movement and 1 with negative movement. Key topics include earnings, clinical trial, IPO, offering. View all SGP news →
SEC Filings
SpyGlass Pharma has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-K, 1 Form SCHEDULE 13G, 1 Form SCHEDULE 13D. The most recent filing was submitted on March 26, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SGP SEC filings →
Insider Radar
Insider buying activity at SpyGlass Pharma over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
operating income reached -$41.4M, and net income was -$39.9M. Diluted earnings per share stood at $-17.98. The company generated -$32.7M in operating cash flow. With a current ratio of 12.67, the balance sheet reflects a strong liquidity position.
Upcoming Events
BIM-DRS first-in-human trial
SpyGlass Pharma has 1 upcoming scheduled event. The next event, "BIM-DRS first-in-human trial", is scheduled for July 1, 2026 (in 94 days). Investors can track these dates to stay informed about potential catalysts that may affect the SGP stock price.
Short Interest History
Days to Cover History
SGP Company Profile & Sector Positioning
SpyGlass Pharma (SGP) operates in the Surgical & Medical Instruments & Apparatus sector and is listed on the NASDAQ.